Study Finds Significant Number of Breast Cancers in Women Under 40Study Finds Significant Number of Breast Cancers in Women Under 40
(MedPage Today) — Women younger than 50 accounted for about a quarter of all breast cancers diagnosed at a large community imaging practice in New York, with a substantial number in women under age 40, a retrospective review found.
Of the nearly…
GLP-1 drugs may reach fewer than one in 10 people who need them, experts predictGLP-1 drugs may reach fewer than one in 10 people who need them, experts predict
The World Health Organization (WHO) has announced its official guidance on the use of GLP-1 drugs for treating obesity. GLP-1 drugs are medications that mimic the natural hormone glucagon-like peptide-1 (GLP-1), which are most commonly used for type 2 diabetes and medical weight loss. The first guideline, released on Dec. 1, aims to address the Read More
Omomyc enhances PARP inhibitor effects and overcomes resistance in breast cancer modelsOmomyc enhances PARP inhibitor effects and overcomes resistance in breast cancer models
Findings from a preclinical study demonstrate that Omomyc—the only direct MYC inhibitor to have successfully completed a phase I clinical trial—causes DNA damage in cancer cells which is synergistically enhanced in combination with poly (ADP-ribose) polymerase inhibitors (PARPi).
GLP-1 Drugs for Cats? High-Dose Wegovy Heads to FDA; Smartphone-Obesity Link in KidsGLP-1 Drugs for Cats? High-Dose Wegovy Heads to FDA; Smartphone-Obesity Link in Kids
(MedPage Today) — Weight-loss injectables for pets? Okava Pharmaceuticals announced plans to kick off a pilot study of a GLP-1 drug for cats with obesity. (New York Times) Novo Nordisk submitted a higher-dose version of semaglutide (Wegovy) to… (MedPage Today) — Weight-loss injectables for pets? Okava Pharmaceuticals announced plans to kick off a pilot Read More
Taking a drug like Ozempic? What you need to know about risks of suicidal thoughts and contraception failureTaking a drug like Ozempic? What you need to know about risks of suicidal thoughts and contraception failure
The rise of GLP-1 drugs such as Ozempic and Mounjaro has been nothing short of meteoric. Originally developed to treat diabetes, these drugs are now widely used for weight loss and have become household names. The rise of GLP-1 drugs such as Ozempic and Mounjaro has been nothing short of meteoric. Originally developed to treat Read More
Overlooked hormone may be deadly driver of postmenopausal breast cancer in women with obesityOverlooked hormone may be deadly driver of postmenopausal breast cancer in women with obesity
A new analysis of research into the most common type of breast cancer has zeroed in on an overlooked hormone that may be responsible for the increased risk of breast cancer death in postmenopausal women with obesity. It also raises the possibility that treatment of these aggressive breast cancers could be improved with the addition of weight-loss drugs known as GLP-1 receptor agonists.
Doctors are seeing more aggressive breast cancer in younger women than expectedDoctors are seeing more aggressive breast cancer in younger women than expected
Younger women are being diagnosed with breast cancer more often than screening guidelines anticipate. Many of these cancers are invasive and harder to treat, especially in those under 40. After analyzing 11 years of data, researchers found that this age group makes up a steady and significant share of diagnoses. The results support a stronger push for earlier risk evaluation.
AI Model Outperformed Density Assessment in Stratifying Breast Cancer RiskAI Model Outperformed Density Assessment in Stratifying Breast Cancer Risk
(MedPage Today) — An image-only artificial intelligence (AI) model recently authorized by the FDA conferred more precise risk stratification in predicting the 5-year risk of breast cancer compared with radiologist-based breast density assessments…
New Guidelines on GLP-1 Drugs for Obesity ReleasedNew Guidelines on GLP-1 Drugs for Obesity Released
(MedPage Today) — GLP-1 receptor agonists for obesity are effective over the long term when paired with lifestyle interventions, but global accessibility must be improved, the World Health Organization (WHO) concluded. The WHO made two recommendations… (MedPage Today) — GLP-1 receptor agonists for obesity are effective over the long term when paired with lifestyle Read More
WHO recommends Ozempic-style weight loss drugs for obesityWHO recommends Ozempic-style weight loss drugs for obesity
Obesity affects more than 1 billion people worldwide and is recognized by the World Health Organization as a chronic, relapsing disease associated with substantial morbidity, mortality, and economic burden. Obesity affects more than 1 billion people worldwide and is recognized by the World Health Organization as a chronic, relapsing disease associated with substantial morbidity, mortality, Read More